- Home
- ABBV vs MUFG Comparison
ABBV vs MUFG Comparison
Compare ABBV & MUFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABBV | MUFG |
|---|---|---|
| Founded | 2012 | 1880 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.9B | 179.9B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABBV | MUFG |
|---|---|---|
| Price | $228.17 | $16.95 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $247.06 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 3.9M |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.05% | 2.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $61,160,000,000.00 | N/A |
| Revenue This Year | $11.90 | $3.25 |
| Revenue Next Year | $8.24 | $9.79 |
| P/E Ratio | $96.45 | ★ $25.47 |
| Revenue Growth | ★ 8.57 | N/A |
| 52 Week Low | $164.39 | $10.46 |
| 52 Week High | $244.81 | $20.15 |
Technical Indicators
Market Signals| Indicator | ABBV | MUFG |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 34.93 |
| Support Level | $220.11 | $14.89 |
| Resistance Level | $229.94 | $18.90 |
| Average True Range (ATR) | 4.76 | 0.46 |
| MACD | -0.43 | -0.24 |
| Stochastic Oscillator | 42.68 | 9.36 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.